A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma

Journal of Gastrointestinal Oncology, 04/09/2012

Although capecitabine and lapatinib is well tolerated, it is not an effective regimen in patients with refractory colorectal adenocarcinoma.

Print Article Summary Cat 2 CME Report